Short Interest in ProPhase Labs, Inc. (NASDAQ:PRPH) Declines By 25.2%

ProPhase Labs, Inc. (NASDAQ:PRPHGet Free Report) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 154,100 shares, a drop of 25.2% from the October 15th total of 206,100 shares. Based on an average daily volume of 83,200 shares, the short-interest ratio is presently 1.9 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ProPhase Labs stock. Vanguard Group Inc. increased its holdings in shares of ProPhase Labs, Inc. (NASDAQ:PRPHFree Report) by 1.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 618,763 shares of the company’s stock after buying an additional 9,416 shares during the period. Vanguard Group Inc. owned 3.43% of ProPhase Labs worth $4,003,000 at the end of the most recent quarter. 9.45% of the stock is owned by hedge funds and other institutional investors.

ProPhase Labs Trading Down 2.4 %

PRPH stock opened at $0.75 on Friday. The company has a 50 day moving average price of $2.20 and a 200 day moving average price of $3.29. ProPhase Labs has a fifty-two week low of $0.66 and a fifty-two week high of $7.48. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 1.58.

ProPhase Labs (NASDAQ:PRPHGet Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.25). The firm had revenue of $2.47 million for the quarter. ProPhase Labs had a negative net margin of 217.64% and a negative return on equity of 60.20%. Equities research analysts anticipate that ProPhase Labs will post -1.23 earnings per share for the current fiscal year.

About ProPhase Labs

(Get Free Report)

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Recommended Stories

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.